The 13-month data from DANCE were separated into two groups based on method of revascularization: atherectomy was performed in 157 limbs, while 124 limbs received angioplasty without atherectomy. For both groups, the primary safety endpoint revealed no post-operative death within 30 days, with major adverse limb events prior to a revascularization reported as 1.6% in the atherectomy group and 0.9% in the angioplasty group. The per-protocol primary efficacy endpoint of primary patency did not widely vary between groups, with 83.6% at 12 months and 80.0% at 13 months in the atherectomy group, and 80.2% at 12 months and 78.2% at 13 months in the angioplasty group. Primary patency was defined as the lack of clinically-driven target lesion revascularization (CD-TLR) or narrowing detected by a duplex ultrasound peak systolic velocity ratio (PSVR) greater than 2.4. Freedom from CD-TLR was 89.6% at 12 months and 88.7% at 13 months in the atherectomy group and was 89.1% at both 12 and 13 months in the angioplasty group. No broad disparities were reported among results by gender, with 13-month primary patency of 79.3% in men and 77.9% in women, or by diabetic status, with 13-month primary patency of 79.5% in diabetics vs. 78.8% in non-diabetics.
"The successful outcomes from the DANCE trial validate the efficient and precise capability of a micro-infusion approach using the Bullfrog device," commented Mercator Chief Executive Officer, Trent Reutiman. "We believe that this represents the first of many potential applications utilizing the Bullfrog for targeted drug delivery with direct visualization."
About the Bullfrog® Micro-Infusion Device
The Mercator Bullfrog Micro-Infusion Device is a FDA 510(k)-cleared and CE-Marked system designed to infuse therapeutic and diagnostic agents directly, non-systemically and safely through blood vessel walls into adventitial tissues. The Bullfrog device is tipped with a balloon-sheathed microneedle, and is compatible with 0.014" guide wires and 5 to 7 French introducer sheaths. The closed balloon provides a protective covering for a tiny, perpendicular-oriented injection needle as it is guided safely through the vasculature to target vessels with diameters of 2 to 8 millimeters.
About the DANCE Trial
The Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy after Femoropopliteal Revascularization (DANCE) trial is a perivascular drug delivery trial that pairs the Bullfrog Micro-Infusion Device with dexamethasone to treat femoral and popliteal arteries after revascularization. DANCE is a prospective, multicenter, single-arm study designed and sponsored by Mercator. The trial is being conducted in 35 centers and its leadership includes co-principal investigators Mahmood Razavi, MD, from St. Joseph's Hospital in Orange, California, and George Adams, MD, from the University of North Carolina-Rex Healthcare, in Raleigh, North Carolina. More information about the DANCE trial is available at https://clinicaltrials.gov/ct2/show/NCT01983449.
About Mercator MedSystems
Mercator MedSystems, Inc. (www.mercatormed.com), based in Emeryville, CA, is a venture-backed, privately held medical technology company. The company develops proprietary catheter-guided micro-infusion systems for targeted delivery of drugs and biologics deep inside the body to treat the root cause of a growing portfolio of medical conditions, including peripheral disease, cardiovascular disease, cancer, hypertension and heart disease.
For Media Inquiries:
firstname.lastname@example.org / 917-553-6808
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clinical-trial-data-presented-from-mercator-medsystems-dance-trial-at-iset-and-linc-300404036.html
SOURCE Mercator MedSystems